卵巢浆液性肿瘤中可溶性CD30／CD30L和CD40／CD40L系统失衡的临床意义  

Clinical significance of soluble CD30/CD30L and CD40/CD40L system imbalance in ovarian serous tumors

作　　者：倪红芬[1] 宋娟芳[1] 吴月红[1] 朱军梅[3] 程爱英[2] 

机构地区：[1]湖州市第三人民医院检验科,313100 [2]湖州市第三人民医院妇科,313100 [3]湖州市中心医院妇产科,313100

出　　处：《中华内分泌外科杂志》2016年第3期225-227,共3页Chinese Journal of Endocrine Surgery

摘　　要：目的探讨可溶性CD30／CD30L和CD40／CD40L系统失衡在卵巢浆液性肿瘤中的临床意义。方法选择浆液性囊腺瘤40例和浆液性囊腺癌30例，另选择年龄和体质量匹配的健康妇女30例作为对照。于术前和术后第7天分别抽取卵巢浆液性肿瘤患者和对照组外周静脉血3ml，分离血清，用酶联免疫吸附法（ELISA）检测血清中可溶性CD30（sCD30）、sCD30L、sCD40和sCD40L水平。结果与对照组相比，浆液性囊腺瘤和浆液性囊腺癌患者血清中sCD30、sCD30L、sCD40和sCD40L水平均显著升高，差异有统计学意义（P〈0．05）；且浆液性囊腺癌较浆液性囊腺瘤患者进一步升高，差异有统计学意义（P〈0．05）。浆液性囊腺瘤和浆液性囊腺癌患者术后第7天，血清中相应可溶性蛋白水平均较术前有显著降低，差异有统计学意义（19〈0．05）。结论检测血清sCD30／sCD30L和sCD40／sCD40L可能对卵巢肿瘤的早期诊断标志及术后病情转归有一定的指导意义。Objective To investigate clinical significance of soluble CD30/CD30L and CD40/CD40L system imbalance in ovarian serous tumors. Methods 40 patients of serous cystadenoma and 30 patients of serous cystadenocarcinoma were selected, and 40 age- and weight-matched healthy women were also recruited as the control group. Peripheral venous blood （3 ml） of the healthy control and patients with ovarian serous tumors before surgery and 7 days after surgery were collected. After separation of serum, ELISA was used to detect levels of sCD30, sCD30L, sCD40 and sCD40L. Results Compared to the control group, levels of sCD30, sCD30L, sCD40 and sCD40L in both serous cystadenoma and serous cystadenocarcinoma groups were significantly in- creased （P〈0.05）. And in those serous cystadenocarcinoma group, levels of such soluble proteins were much higher than in serous cystadenoma group （P〈0.05）. 7 days after surgery, levels of such soluble proteins were sig- nificantly decreased in both serous cystadenoma and serous cystadenocarcinoma groups （P〈0.05）. Conclusion Detection of serum sCD30/sCD30L and sCD40/sCD40L is possible to have a certain guiding significance to early diagnosis of ovarian tumors and the prognosis of patients.

关 键 词：卵巢肿瘤 CD30/CD30L CD40/CD40L 

分 类 号：R737.31[医药卫生—肿瘤] R730.43[医药卫生—临床医学]